Liquid Biopsy Market Driven By Rising number of cancer patients in the world


Posted February 2, 2017 by Tarunc22

Liquid biopsy is an advanced cancer diagnostic test carried out using biofluids such as blood, CSF, plasma and urine for cancer detection.

 
Liquid Biopsy Market deals with the biopsy test for cancer using liquid biopsy technology. Also known as fluid biopsy, liquid biopsy is a blood test for cancer detection. Biopsy test for cancer is done by taking a sample tissue from the body, to examine closely with microscope.
This biopsy is recommended when initial test prove that a particle tissue is not normal. Such tests are needed when a doctor sees traces of cancer cells or RNA or DNA of cancer in the blood and to suggest what are the treatments required for the patient.
Request For Sample Brochure @ http://industryarc.com/pdfdownload.php?id=16055
Scope & Regional Forecast of the Liquid Biopsy Market
The Liquid Biopsy Market is segmented by cancer type, circulating biomarker, end-user and geography. On the basis of cancer type the Liquid Biopsy Market can be divided as Lung cancer, breast cancer, colorectal cancer, prostate cancer and liver cancer. Depending on circulating biomarker, it includes Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA (CTDNA). The end-users of liquid biopsy technology are Reference Laboratory and Research Centers.
Liquid biopsy is an advanced technology and is different from the traditional biopsy that is done by removing and examining the tissue. In liquid biopsy cancer screening, liquid such as blood sample is taken to examine the effect of cancer treatment being done on the patient. It shows whether the treatment is working, the drugs are affecting the tumors or not and to see if there is a need to change the treatment. Thus, this test for cancer is very mush effective and in a non-invasive way.
Geographically, the Liquid Biopsy Market is widespread in America, Europe, APAC and Rest of the World. North America is the largest market for Liquid Biopsy Market as a number of liquid biopsies for cancer have been done here in the recent year. Asia-Pacific is considered as the fastest growing region owing to an increase in awareness of liquid biopsy and advancement in the medical research technologies.
Inquiry Before Buying @ http://industryarc.com/inquiry-before-buying.php?id=16055
Segmentations & Key Players Involved in the Liquid Biopsy Market
According to IndustryARC research, the Liquid Biopsy Market can be divided into various segmentations on the basis of –
Cancer Type: Lung cancer, breast cancer, colorectal cancer, prostate cancer and liver cancer
Circulating Biomarker: Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA (CTDNA)
End-User: Reference Laboratory and Research Centers
Geography: America, Europe, APAC, Rest of the World
Some of the key players involved in the Liquid Biopsy Market according to IndustryARC are as follows:
• Guardant Health Inc.
• Fraunhofer-Gesellschaft
• MDX Health SA
• Qiagen
• Biocept, Inc.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Industryarc
Country India
Categories Health
Tags biopsy test for cancer , blood test for cancer detection , liquid biopsies for cancer , liquid biopsy , liquid biopsy cancer screening , liquid biopsy market , liquid biopsy technology , test for cancer
Last Updated February 2, 2017